|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 1999~2006年急性冠脉综合征患者死亡及心力衰竭发生率降低显示文摘背景:有关药物和介入治疗对ST段抬高型和非ST段抬高型急性冠脉综合征(non—ST-segment elevation acute coronary syndrome,NSTE ACS)患者的作用,随机试验已经提供了足够的证据,但是是否已经转化为相应的临床变化还不清楚。
目的:确定ST段抬高型心肌梗死(ST-segment elevation myocardial infarction,STEMI)和NSTE ACS患者的院内治疗改变是否伴随临床结果的改善。
设计、地点及患者:全球急性冠脉事件注册研究(Global Registry of Acute Coronary Events,GRACE)是一项多国家队列研究。自1999年7月1日至2006年12月31日,该研究共入选并随访了来自14个国家、113家医院的44372例ACS患者。
主要观测指标:当前循证药物和介入治疗应用的趋势及患者预后(死亡、充血性心力衰竭、肺水肿、心源性休克、卒中和心肌梗死)。
结果:随着研究时间的进展,相关药物的应用增加(β-受体阻滞剂、他汀类药物、血管紧张素转换酶抑制剂、行或未行经皮冠状动脉介入治疗[percutaneous coronary intervention,PCI]患者应用噻氯毗啶、糖蛋白Ⅱb/Ⅲa抑制剂和低分子肝素;P〈0.001)。STEMI患者药物再灌注治疗下降了22个百分点(95%可信区间[confidence interval,CI],-27~-17),而直接PCI增加了37个百分点(95%CI,33—41)。在NSTEMI患者中,PCI的比例显著升高了18个百分点(95%CI,15~20)。充血性心力衰竭和肺水肿在STEMI患者中降低了9个百分点(95%CI,-12~-6),在NSTEACS患者中降低了6.9个百分点(95%CI,-8.4~-4.7)。STEMI患者的院内死亡率降低了18个百分点(95%CI,-5.3~-1.9),心源性休克降低了24个百分点(95%CI,-4.3~-0.5)。校正了危险评分后,NSTEACS患者的院内死亡率降低了0.7个百分点(95%CI,-1.7~0.3);STEMI患者6个月随访时卒中发生率降低了0.8个百分点(95%CI,-1.7~0.1),心肌梗死发生率降低了2.8个百分点(95%CI,-6.4~0.9)。NSTEACS患者6个月死亡率降低了1.6个百分点(95%CI,-3.0~-0.1),卒中发生率降低了0.7个百分点(95%CI,-1.4~0.1)。
结论:在本项多国家观察性研究中,ACS患者治疗的改善与6个月新发心力衰竭、死亡率、卒中和心肌梗死发生率显著降低相关。 | Keith A. A. Fox Philippe Gabriel Steg Kim A. Eagle Shaun G. Goodman Frederick A. Anderson Christopher B. Granger Marcus D. Flather Andrzej Budaj Ann Quill Joel M. Gore 康俊萍(译) 马长生(校) | 2007 | 美国医学会杂志(中文版)2007，26，6： | 6 |
| 2 | Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma显示文摘Although genome-wide association studies have identified more than eighty genetic variants associated with non-small cell lung cancer(NSCLC)risk,biological mechanisms of these variants remain largely unknown.By integrating a large-scale genotype data of 15581 lung adenocarcinoma(AD)cases,8350 squamous cell carcinoma(SqCC)cases,and 27355 controls,as well as multiple transcriptome and epigenomic databases,we conducted histology-specific meta-analyses and functional annotations of both reported and novel susceptibility variants.We identified 3064 credible risk variants for NSCLC,which were overrepresented in enhancer-like and promoter-like histone modification peaks as well as DNase I hypersensitive sites.Transcription factor enrichment analysis revealed that USF1 was AD-specific while CREB1 was SqCC-specific.Functional annotation and genebased analysis implicated 894 target genes,including 274 specifics for AD and 123 for SqCC,which were overrepresented in somatic driver genes(ER=1.95,P=0.005).Pathway enrichment analysis and Gene-Set Enrichment Analysis revealed that AD genes were primarily involved in immune-related pathways,while SqCC genes were homologous recombination deficiency related.Our results illustrate the molecular basis of both wellstudied and new susceptibility loci of NSCLC,providing not only novel insights into the genetic heterogeneity between AD and SqCC but also a set of plausible gene targets for post-GWAS functional experiments. | Na Qin Yuancheng Li Cheng Wang Meng Zhu Juncheng Dai Tongtong Hong Demetrius Albanes Stephen Lam Adonina Tardon Chu Chen Gary Goodman Stig EBojesen Maria Teresa Landi Mattias Johansson Angela Risch H-Erich Wichmann Heike Bickeboller Gadi Rennert Susanne Arnold Paul Brennan John KField Sanjay Shete Loic Le Marchand Olle Melander Hans Brunnstrom Geoffrey Liu Rayjean JHung Angeline Andrew Lambertus AKiemeney Shan Zienolddiny Kjell Grankvist Mikael Johansson Neil Caporaso Penella Woll Philip Lazarus Matthew BSchabath Melinda CAldrich Victoria LStevens Guangfu Jin David CChristiani Zhibin Hu Christopher IAmos Hongxia Ma Hongbing Shen | 2021 | Frontiers of Medicine2021，15，2： | 3 |
| 3 | Hierarchical modeling identifies novel lung cancer susceptibility variants in inflammation pathways among 10,140 cases and 11,012 controls显示文摘 | Darren R. Brenner Paul Brennan Paolo Boffetta Christopher I. Amos Margaret R. Spitz Chu Chen Gary Goodman Joachim Heinrich Heike Bickeb?ller Albert Rosenberger Angela Risch Thomas Muley John R. McLaughlin Simone Benhamou Christine Bouchardy Juan Pablo Lew | 2013 | Human Genetics2013，，： | 1 |
| 4 | Transcritical carbon dioxide microchannel heat pump water heaters: Part II e System simulation and optimization 显示文摘 | Christopher Goodman Brian M Fronk Srinivas Gari- mella | 2011 | Science Direct2011，34，5： | 1 |
| 5 | Functional complementation of anthocyanin sequestration in the vacuole by widely divergent glutathione S- transferases显示文摘 | MARK R ALFENITO ERIK SOUER CHRISTOPHER D Goodman | 1998 | Plant Cell1998，10，： | 1 |
| 6 | Prevalence of Human Papillomavirus Types in Invasive Cervical Cancers From 7 US Cancer Registries Before Vaccine Introduction显示文摘 | Claudia Hopenhayn Amy Christian Warren Jay Christian Meg Watson Elizabeth R. Unger Charles F. Lynch Edward S. Peters Edward J. Wilkinson Youjie Huang Glenn Copeland Wendy Cozen Maria Sibug Saber Marc T. Goodman Brenda Y. Hernandez Martin Steinau Christoph | 2014 | Journal of Lower Genital Tract Disease2014，，2： | 1 |
| 7 | Upper abdominal normal organ contouring guidelines and atlas: A Radiation Therapy Oncology Group consensus显示文摘 | Salma K. Jabbour Sameh A. Hashem Walter Bosch Tae Kyoung Kim Steven E. Finkelstein Bethany M. Anderson Edgar Ben-Josef Christopher H. Crane Karyn A. Goodman Michael G. Haddock Joseph M. Herman Theodore S. Hong Lisa A. Kachnic Harvey J. Mamon Jason R. Pant | 2014 | Practical Radiation Oncology2014，，： | 1 |
| 8 | Human Papillomavirus Prevalence in Invasive Anal Cancers in the United States Before Vaccine Introduction显示文摘 | Martin Steinau Elizabeth R. Unger Brenda Y. Hernandez Marc T. Goodman Glenn Copeland Claudia Hopenhayn Wendy Cozen Maria S. Saber Youjie Huang Edward S. Peters Charles F. Lynch Edward J. Wilkinson Mangalathu S. Rajeevan Christopher Lyu Mona Saraiya | 2013 | Journal of Lower Genital Tract Disease2013，，4： | 1 |
| 9 | Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graftversus-host disease after liver transplantation显示文摘 | Anna L. Taylor Paul Gibbs Surendran Sudhindran Tim Key Reyna S. Goodman C. Helen Morgan Christopher J. E. Watson Luc Delriviere Graeme J. Alexander Neville V. Jamieson J. Andrew Bradley Craig J. Taylor | 2004 | Transplantation2004，，3： | 1 |
| 10 | EUS-guided fiducial placement for image-guided radiation therapy in GI malignancies by using a 22-gauge needle (with videos )显示文摘 | Christopher J. DiMaio Satish Nagula Karyn A. Goodman Alice Y. Ho Arnold J. Markowitz Mark A. Schattner Hans Gerdes | 2010 | Gastrointestinal Endoscopy2010，，7： | 1 |
| 11 | A multidrug resistanceassociated protein involved in anthocyanin transport in Zea mays 显示文摘 | Goodman Christopher Dean Casati Paula Walbot Virginia | 2004 | Plant Cell2004，16，： | 1 |
| 12 | 非ST段抬高急性冠脉综合征患者随机应用依诺肝素或普通肝素抗凝治疗的疗效和出血并发症:系统综述显示文摘背景:抗凝疗法已成为急性冠脉综合征(acute coronary syndrome,ACS)治疗指南推荐的标准疗法。但是,最近某些试验在ACS患者中对依诺肝素(enoxaparin)与普通肝素(unfractionated heparin)的应用进行了比较,发现这些抗凝疗法的疗效及安全性并不及既往试验结果。目的:有6项随机对照试验对依诺肝素与普通肝素治疗ACS患者进行了比较,对其终点(即全因死亡及非致死性心肌梗死)、输血与大出血进行系统评估。资料来源:从杜克临床研究所(Duke Clinical Research Institute)获取ESSENCE、A to Z及SYNERGY试验的原始数据。由TIMI 11B、ACUTEⅡ及INTERACT研究的主要研究人员提供各自的基线特征和事件发生频率。研究选取:在非ST段抬高ACS患者中比较依诺肝素与普通肝素的6项随机对照试验均人选进行分析。数据提取:从全部试验人群和随机分组前未接受抗凝治疗的亚人群中获取疗效终点和安全性终点。数据综合:应用随机效应经验性贝叶斯模型(random—effects empirical Bayes model),系统评估21946例患者的结果。依诺肝素与普通肝素30天死亡率无显著差异(3.0%比3.0%,优势比[odds ratio,OR],1.00;95%可信区间[confidence interval,CI],0.85~1.17)。在所有试验人群中,依诺肝素与普通肝素相比,30天死亡或非致死性心肌梗死(myocardial infarction,MI)联合终点显著下降,具有统计学差异(10.1%比11.0%;OR,0.91;95%CI,0.83~0.99;所需治疗例数107)。随机分组前未接受抗凝治疗的依诺肝素组患者30天死亡或MI联合终点亦显著下降,具有统计学差异(8.0%比9.4%;OR,0.81;95%CI,0.70~0.94;所需治疗例数72)。随机分组后第7天,总体安全人群或者随机分组前未接受抗凝治疗的人群输血(OR,1.01;95%CI,0.89~1.14)或大出血的发生率(OR,1.04;95%CI,0.83~1.30)无显著差异。结论:对近22000例各类ACS患者进行系统回顾发现,在预防死亡或MI联合终点方面依诺肝素较普通肝素更有效。 | John L. Petersen Kenneth W. Mahaffey Vic Hasselblad Elliott M. Antman Marc Cohen Shaun G. Goodman Anatoly Langer Michael A. Blazing Anne Le-Moigne-Amrani James A. de Lemos Christopher C. Nessel Robert A. Harrington James J. Ferguson Eugene Braunwald Robert M. Califf 徐成斌(译) | 2005 | 美国医学会杂志(中文版)2005，24，4： | 0 |
| 13 | Practice patterns in FNA technique: A survey analysis显示文摘AIM: To ascertain fine needle aspiration(FNA) tech-niques by endosonographers with varying levels of ex-perience and environments.METHODS: A survey study was performed on United States based endosonographers. The subjects complet-ed an anonymous online electronic survey. The main outcome measurements were differences in needle choice, FNA technique, and clinical decision making among endosonographers and how this relates to years in practice, volume of EUS-FNA procedures, and prac-tice environment.RESULTS: A total of 210(30.8%) endosonographers completed the survey. Just over half(51.4%) identified themselves as academic/university-based practitioners. The vast majority of respondents(77.1%) identified themselves as high-volume endoscopic ultrasound(EUS)(> 150 EUS/year) and high-volume FNA(> 75 FNA/year) performers(73.3). If final cytology is non-diagnostic, high-volume EUS physicians were more likely than low volume physicians to repeat FNA with a core needle(60.5% vs 31.2%; P = 0.0004), and low volume physicians were more likely to refer patients for either surgical or percutaneous biopsy,(33.4% vs 4.9%, P < 0.0001). Academic physicians were more likely to repeat FNA with a core needle(66.7%) compared to community physicians(40.2%, P < 0.001). CONCLUSION: There is significant variation in EUS-FNA practices among United States endosonographers. Differences appear to be related to EUS volume and practice environment. | Christopher J DiMaio Jonathan M Buscaglia Seth A Gross Harry R Aslanian Adam J Goodman Sammy Ho Michelle K Kim Shireen Pais Felice Schnoll-Sussman Amrita Sethi Uzma D Siddiqui David H Robbins Douglas G Adler Satish Nagula | 2014 | World Journal of Gastrointestinal Endoscopy2014，6，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员